Mumbai, Baltimore, July 13, 2021: Global pharma major Lupin Limited (Lupin) today announced the U.S. launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin® Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Tavaborole Topical Solution (RLD: Kerydin®), 5% has an estimated annual sales of USD 53 million in the U.S. (IQVIA MAT May 2021).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
For further information or queries please contact
Head – Corporate Communications
*Safe Harbor Statement
Kerydin® is a registered trademark of Anacor Pharmaceuticals, Inc